- Conditions
- Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
- Interventions
- ASP5834, panitumumab
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 11
- States / cities
- Santa Monica, California • Atlanta, Georgia • Jefferson, Louisiana + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 4,666
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Hepatitis C
- Interventions
- BMS-824393
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 6
- States / cities
- Anaheim, California • Cypress, California • Miami, Florida + 3 more
- Conditions
- Binge Eating, Depression
- Interventions
- Duloxetine, Placebo
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- End Stage Liver Disease
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2030
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Loma Linda, California • San Francisco, California + 9 more
- Conditions
- Pain, Appendicitis, Bias, Racial, Fractures, Bone
- Interventions
- Department-level audit and feedback and electronic health record-embedded clinical decision support
- Behavioral
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 0 Years and older
- Enrollment
- 22,032 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Ornithine Carbamoyltransferase Deficiency (Disorder), Urea Cycle Disorders, Inborn
- Interventions
- ECUR-506
- Genetic
- Lead sponsor
- iECURE, Inc.
- Industry
- Eligibility
- 24 Hours to 7 Months · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 3 more
- Conditions
- Cancer, Cancer Metastatic, Neoplasms, Breast Cancer, Lung Cancer, Thyroid Cancer, Lymphoma, Lymphoma, Non-Hodgkin, Hodgkin Lymphoma, Leukemia, Sarcoma, Skin Cancer, Bone Cancer, Gynecologic Cancer, Pancreas Cancer, Multiple Myeloma, Colorectal Cancer, Gastrointestinal Cancer, Prostate Cancer, Glioblastoma, Brain Cancer, Head and Neck Cancer
- Interventions
- Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
- Behavioral
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Combination antiviral therapy, Placebo
- Drug
- Lead sponsor
- University of Alberta
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • St Louis, Missouri
- Conditions
- Hepatic Encephalopathy, Cirrhosis
- Interventions
- ipod games
- Behavioral
- Lead sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
- Federal
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Non-alcoholic Steatohepatitis, Hepatic Impairment, Cirrhosis
- Interventions
- TVB-2640 - 50 mg
- Drug
- Lead sponsor
- Sagimet Biosciences Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 2
- States / cities
- Orlando, Florida • San Antonio, Texas
- Conditions
- Cirrhosis, Hepatic Encephalopathy
- Interventions
- One meal
- Other
- Lead sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, NAFLD - Nonalcoholic Fatty Liver Disease
- Interventions
- CRV431 75mg, Placebo (1 softgel), CRV431 225mg, Placebo (3 softgels)
- Drug
- Lead sponsor
- Hepion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 9
- States / cities
- Orange, California • Poway, California • Miami, Florida + 5 more
- Conditions
- Nonalcoholic Steatohepatitis (NASH) With Fibrosis
- Interventions
- Elafibranor, Placebo
- Drug
- Lead sponsor
- Genfit
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2,157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 153
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 98 more
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Aplastic Anemia, Burkitt Lymphoma, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Juvenile Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Paroxysmal Nocturnal Hemoglobinuria, Peripheral T-cell Lymphoma, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Secondary Myelofibrosis, Severe Combined Immunodeficiency, Severe Congenital Neutropenia, Shwachman-Diamond Syndrome, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Waldenstrom Macroglobulinemia, Wiskott-Aldrich Syndrome
- Interventions
- fludarabine phosphate, melphalan, total-body irradiation, tacrolimus, mycophenolate mofetil, methotrexate, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Drug · Radiation · Other + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 3 Years to 75 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Colorectal Cancer, Diarrhea
- Interventions
- irinotecan hydrochloride, octreotide acetate
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 2
- States / cities
- East Hanover, New Jersey • Princeton, New Jersey
- Conditions
- Non-Alcoholic Fatty Liver Disease, Insulin Resistance, High Intensity Interval Training, Childhood Obesity
- Interventions
- High-Intensity Interval Training (HIIT)
- Other
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- Other
- Eligibility
- 13 Years to 18 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Little Rock, Arkansas
- Conditions
- Diabetes Mellitus Type 2, Non Alcoholic Fatty Liver Disease, Obesity
- Interventions
- Amlexanox
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma, Lymphoma, Primary Central Nervous System Lymphoma
- Interventions
- CC-122
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 17
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 13 more
- Conditions
- Lung Cancer (Diagnosis), Liver Cancer, Adult, Pancreatic Cancer, Thoracic Cancers, Abdominal Cancer
- Interventions
- Next Generation Delivery System (NGDS)
- Device
- Lead sponsor
- Varian, a Siemens Healthineers Company
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Cleveland, Ohio
- Conditions
- Postoperative Nausea and Vomiting
- Interventions
- APD421, Placebo
- Drug
- Lead sponsor
- Acacia Pharma Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 705 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 4
- States / cities
- Miami, Florida • Durham, North Carolina • Winston-Salem, North Carolina + 1 more
- Conditions
- Insulin Resistance, Obesity, Cardiovascular Diseases, Cognitive Impairment, Physical Disability, Depression, Inflammation, Hormone Deficiency, Physical Inactivity, Hyperlipidemias, Hypertension, Overeating
- Interventions
- GLY-LOW
- Biological
- Lead sponsor
- Hoskinson Health and Wellness Clinic
- Industry
- Eligibility
- 56 Years and older · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Gillette, Wyoming
- Conditions
- Binge-Eating Disorder
- Interventions
- Circadian Reset Technology, VR Headset
- Behavioral
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bulimia Nervosa, Bulimia; Atypical, Binge Eating, Binge-Eating Disorder
- Interventions
- Reward Re-Training, Supportive Therapy
- Behavioral
- Lead sponsor
- Drexel University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Gastroparesis
- Interventions
- Not listed
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana